Johnson & Johnson : JNJ

All Johnson & Johnson Articles

1194 Articles

Paul Ausick | Jul 17, 2015 at 4:01 PM EDT

The 4 Stocks That Sank the DJIA on Friday

July 17, 2thinkstock015: Markets opened mixed on Friday as the Nasdaq traded higher right from the opening bell and the…

Lee Jackson | Jul 16, 2015 at 9:35 AM EDT

UBS Makes Summer Changes to Dividend Ruler Stocks Portfolio

A new report from UBS includes changes to the firm's Dividend Ruler stocks portfolio. Also featured are the current four…

Chris Lange | Jul 14, 2015 at 8:40 AM EDT

Johnson & Johnson Posts Q2 Earnings Beat

Johnson & Johnson reported better-than-expected second-quarter financial results before the markets opened Tuesday.

Chris Lange | Jul 13, 2015 at 11:10 AM EDT

What to Expect From Johnson & Johnson Earnings

Johnson & Johnson is expected to report its second-quarter financial results Tuesday morning before the markets open.

Chris Lange | Jul 12, 2015 at 9:10 AM EDT

6 Key DJIA Earnings for the Week Ahead

Earnings season for the second quarter of the calendar year has kicked off, and 24/7 Wall St. has put together…

Lee Jackson | Jul 7, 2015 at 10:20 AM EDT

UBS Makes Changes to Dividend Ruler Stock List

With the Greek debacle throwing some very cold water on the market, it makes sense for investors to use cash…

Chris Lange | Jul 7, 2015 at 7:35 AM EDT

5 Big Upcoming FDA Decisions Expected in July

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and…

Paul Ausick | Jun 18, 2015 at 4:01 PM EDT

The 4 Stocks That Dominated the DJIA on Thursday

thinkstockJune 18, 2015: Markets opened higher on Thursday based on the FOMC’s decision to leave interest rates alone and generally…

Douglas A. McIntyre | Jun 13, 2015 at 9:25 AM EDT

Great Stocks for the Elderly

Older Americans, in many cases, have lost their tolerance for financial risk and they want to protect the size of…

Chris Lange | Jun 8, 2015 at 1:00 PM EDT

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical…

Lee Jackson | Jun 6, 2015 at 9:15 AM EDT

Insider Buying Still Strong as Market Volatility Spikes

The jump in market volatility did not deter executives and 10% shareholders this week, and insider buying stayed solid.

Jon C. Ogg | Jun 2, 2015 at 10:45 AM EDT

5 Stocks That Warren Buffett Should Sell — or Add to the Stake

It turns out that Buffett has five public stocks that used to be far larger stakes or which seem like…

Paul Ausick | May 22, 2015 at 4:01 PM EDT

The 4 Stocks That Sank the DJIA on Friday

thinkstockMay 22 2015: Markets opened mixed on Friday on a day that was tough on blue chips. The energy sector…

Jon C. Ogg | May 21, 2015 at 8:05 AM EDT

10 Companies to Own for the Next Decade

Back in November of 2010, 24/7 Wall St. first issued a list of stocks to own for the next decade.…

Chris Lange | May 20, 2015 at 9:55 AM EDT

Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?

Johnson & Johnson has been working on its pharmaceuticals pipeline for a while, and plans on continuing to do so.

1 … 42 43 44 45 46 … 80

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

The 4 Stocks That Sank the DJIA on Friday

UBS Makes Summer Changes to Dividend Ruler Stocks Portfolio

Johnson & Johnson Posts Q2 Earnings Beat

What to Expect From Johnson & Johnson Earnings

6 Key DJIA Earnings for the Week Ahead

UBS Makes Changes to Dividend Ruler Stock List

5 Big Upcoming FDA Decisions Expected in July

The 4 Stocks That Dominated the DJIA on Thursday

Great Stocks for the Elderly

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Insider Buying Still Strong as Market Volatility Spikes

5 Stocks That Warren Buffett Should Sell — or Add to the Stake

The 4 Stocks That Sank the DJIA on Friday

10 Companies to Own for the Next Decade

Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

The 4 Stocks That Sank the DJIA on Friday

UBS Makes Summer Changes to Dividend Ruler Stocks Portfolio

Johnson & Johnson Posts Q2 Earnings Beat

What to Expect From Johnson & Johnson Earnings

6 Key DJIA Earnings for the Week Ahead

UBS Makes Changes to Dividend Ruler Stock List

5 Big Upcoming FDA Decisions Expected in July

The 4 Stocks That Dominated the DJIA on Thursday

Great Stocks for the Elderly

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Insider Buying Still Strong as Market Volatility Spikes

5 Stocks That Warren Buffett Should Sell — or Add to the Stake

The 4 Stocks That Sank the DJIA on Friday

10 Companies to Own for the Next Decade

Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

Featured Reads

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings